|Other Names||Melanoma-associated antigen C1, Cancer/testis antigen 71, CT71, MAGE-C1 antigen, MAGEC1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6175a was selected from the C-term region of human MAGEC1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Expressed in testis and in tumors of a wide variety of histologic types|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MAGEC1 is a member of the melanoma antigen gene (MAGE) family. The proteins of this family are tumor-specific antigens that can be recognized by autologous cytolytic T lymphocytes. This protein contains a large number of unique short repetitive sequences in front of the MAGE-homologous sequence, thus is about 800 residues longer than the other MAGE proteins. This gene is expressed in a significant proportion of tumors of various histological types, whereas it is silent in normal tissues, except testis. The function of this gene is unknown.
Jungbluth, A.A., et al., Int. J. Cancer 99(6):839-845 (2002).Chen, Y.T., et al., Proc. Natl. Acad. Sci. U.S.A. 95(12):6919-6923 (1998).Lucas, S., et al., Cancer Res. 58(4):743-752 (1998).Lim, S.H., et al., Eur. J. Haematol. 67 (5-6), 332-334 (2001).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.